Liver-X-receptor activator prevents homocysteine-induced production of IgG antibodies from murine B lymphocytes via the ROS-NF-κB pathway

Biochemical and Biophysical Research Communications

Volumn 357, Issue 3, 2007, Pages 772-778

  Chang, Lina ^a   Zhang, Zhenmin ^b   Li, Wenjing ^b   Dai, Jing ^b   Guan, Youfei ^b   Wang, Xian ^a,b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

B lymphocytes; Free radicals; LXR

Indexed keywords

HOMOCYSTEINE; HORMONE RECEPTOR BLOCKING AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G ANTIBODY; LIPOPOLYSACCHARIDE; LIVER X RECEPTOR; REACTIVE OXYGEN METABOLITE; SCAVENGER; TO 901317; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; HYPERHOMOCYSTEINEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; SPLEEN LYMPHOCYTE;

ANIMALS; APOLIPOPROTEINS E; B-LYMPHOCYTES; CELL LINE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; IMMUNOGLOBULIN G; LEUPEPTINS; LIPOPOLYSACCHARIDES; LUCIFERASES; METALLOPORPHYRINS; MICE; MICE, KNOCKOUT; NF-KAPPA B; REACTIVE OXYGEN SPECIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SPLEEN; SULFONAMIDES; TIME FACTORS; TRANSFECTION;

MURINAE; MUS;

EID: 34247643330     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.04.016     Document Type: Article

References (26)

1. Malinow M.R., Nieto F.J., Szklo M., and Chambless L.E. Bond G, Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults, The atherosclerosis risk in communities study. Circulation 87 (1993) 1107-1113
2. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., and Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. 324 (1999) 1149-1155
3. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
4. Song L., Leung C., and Schindler C. Lymphocytes are important in early atherosclerosis. J. Clin. Invest. 108 (2001) 251-259
5. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1876-1890
6. Xu Q.B., Oberhuber G., Gruschwitz M., and Wick G. Immunology of atherosclerosis: cellular composition and major histocompatibility complex class II antigen expression in aortic intima, fatty streaks, and atherosclerotic plaques in young and aged human specimens. Clin. Immunol. Immunopathol. 56 (1990) 344-359
7. Zhang Q., Zeng X., Guo J., and Wang X. Effects of homocysteine on murine splenic B lymphocyte proliferation and its signal transduction mechanism. Cardiovasc. Res. 52 (2001) 328-336
8. Weiss N., Heydrick S.J., Postea O., Keller C., Jr Keaney J.F., and Loscalzo J. Influence of hyperhomocysteinemia on the cellular redox state-impact on homocysteine-induced endothelial dysfunction. Clin. Chem. Lab. Med. 41 (2003) 1455-1461
9. Zeng X., Dai J., Remick D.G., and Wang X. Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes. Circ. Res. 93 (2003) 311-320
10. Steffensen K.R., and Gustafsson J.A. Putative metabolic effects of the liver-X-receptor (LXR). Diabetes 53 (2004) S36-S42
11. Joseph S.B., and Tontonoz P. LXRs: new therapeutic targets in atherosclerosis. Curr. Opin. Pharmacol. 3 (2003) 192-197
12. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., and Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver-X-receptors. Nat. Med. 9 (2003) 213-219
13. Dai J., Li W., Chang L., Zhang Z., Tang C., Wang N., Zhu Y., and Wang X. Role of redox factor-1 in hyperhomocysteinemia-accelerated atherosclerosis. Free Radic. Biol. Med. 41 (2006) 1566-1577
14. Bryan R.G., Li Y., Lai J.H., Van M., Rice N.R., Rich R.R., and Tan T.H. Effect of CD28 signal transduction on c-Rel in human peripheral blood T cells. Mol. Cell. Biol. 14 (1994) 7933-7942
15. Wu J., Zhang Y., Wang N., Davis L., Yang G., Wang X., Zhu Y., Breyer M.D., and Guan Y. Liver-X-receptor α mediates cholesterol efflux in glomerular mesangial cells. Am. J. Physiol. Renal Physiol. 287 (2004) F886-F895
16. Shoenfeld Y., Sherer Y., and Harats D. Atherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol. 22 (2001) 293-295
17. Libby P., and Hansson G.K. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab. Invest. 64 (1991) 5-15
18. Vlaicu R., Rus H.G., Niculescu F., and Cristea A. Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis 55 (1985) 35-50
19. Hansson G.K., Holm J., and Kral J.G. Accumulation of IgG and complement factor C3 in human arterial endothelium and atherosclerotic lesions. Acta. Pathol. Microbiol. Immunol. Scand [A] 92 (1984) 429-435
20. Houtkamp M.A., de Boer O.J., van der Loos C.M., van der W.A.C., and Becker A.E. Adventitial infiltrates associated with advanced atherosclerotic plaques: structural organization suggests generation of local humoral immune responses. J. Pathol. 193 (2001) 263-269
21. Yamamoto Y., and Gaynor R.B. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem. Sci. 29 (2004) 72-79
22. Peng S.L. Transcription factors in the pathogenesis of autoimmunity. Clin. Immunol. 110 (2004) 112-123
23. Ginn-Pease M.E., and Whisler R.L. Redox signals and NF-kB activation in T cells. Free Radic. Biol. Med. 25 (1998) 346-361
24. Lund E.G., Menke J.G., and Sparrow C.P. Liver-X-receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1169-1177
25. Zhou X., Caligiuri G., Hamsten A., Lefvert A.K., and Hansson G.K. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 108-114
26. Caligiuri G., Nicoletti A., Poirier B., and Hansson G.K. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J. Clin. Invest. 109 (2002) 745-753